Summary of the payer’s published policy. Not a coverage determination — confirm with the payer before submitting.
Recorded changes
83,427 on record
Recorded policy changes, newest first| Recorded | Payer | Policy | Change |
|---|
| Aug 2, 2026 | Independence Blue Cross | Allergy ImmunotherapyPayerPolicy · IBX-MEDICARE-ADVANTAGE-MA07-055 | New policy |
|---|
| Aug 2, 2026 | Independence Blue Cross | Alglucosidase alfa (e.g., Lumizyme), Avalglucosidase alfa-ngpt (Nexviazyme ), Cipaglucosidase alfa-atga (Pombiliti )PayerPolicy · IBX-MEDICARE-ADVANTAGE-MA08-036 | New policy |
|---|
| Aug 2, 2026 | Independence Blue Cross | Alemtuzumab (Lemtrada)PayerPolicy · IBX-MEDICARE-ADVANTAGE-MA08-015 | New policy |
|---|
| Aug 2, 2026 | Independence Blue Cross | Air Ambulance ServicesPayerPolicy · IBX-MEDICARE-ADVANTAGE-MA12-007 | New policy |
|---|
| Aug 2, 2026 | Independence Blue Cross | Agalsidase beta (Fabrazyme) and pegunigalsidase alfa-iwxj (Elfabrio)PayerPolicy · IBX-MEDICARE-ADVANTAGE-MA08-033 | New policy |
|---|
| Aug 2, 2026 | Independence Blue Cross | Ado-Trastuzumab Emtansine (Kadcyla)PayerPolicy · IBX-MEDICARE-ADVANTAGE-MA08-066 | New policy |
|---|
| Aug 2, 2026 | Independence Blue Cross | ADAMTS13, recombinant-krhn (Adzynma)PayerPolicy · IBX-MEDICARE-ADVANTAGE-MA08-171 | New policy |
|---|
| Aug 2, 2026 | Independence Blue Cross | Acute Care Facility Inpatient TransfersPayerPolicy · IBX-MEDICARE-ADVANTAGE-MA12-003 | New policy |
|---|
| Aug 2, 2026 | Independence Blue Cross | AcupuncturePayerPolicy · IBX-MEDICARE-ADVANTAGE-MA12-004 | New policy |
|---|
| Aug 2, 2026 | Independence Blue Cross | AbortionPayerPolicy · IBX-MEDICARE-ADVANTAGE-MA11-010 | New policy |
|---|
| Aug 2, 2026 | Independence Blue Cross | Ablation of Lung TumorsPayerPolicy · IBX-MEDICARE-ADVANTAGE-MA11-052 | New policy |
|---|
| Aug 2, 2026 | Independence Blue Cross | Abatacept (Orencia) for Injection for Intravenous UsePayerPolicy · IBX-MEDICARE-ADVANTAGE-MA08-028 | New policy |
|---|
| Aug 2, 2026 | Independence Blue Cross | Zolbetuximab-clzb (Vyloy)PayerPolicy · IBX-COMMERCIAL-08-02-36 | New policy |
|---|
| Aug 2, 2026 | Independence Blue Cross | Zenocutuzumab-zbco (Bizengri)PayerPolicy · IBX-COMMERCIAL-08-02-38 | New policy |
|---|
| Aug 2, 2026 | Independence Blue Cross | Zanidatamab-hrii (Ziihera)PayerPolicy · IBX-COMMERCIAL-08-02-39 | New policy |
|---|
| Aug 2, 2026 | Independence Blue Cross | X-rays Associated with Fractures in the Office SettingPayerPolicy · IBX-COMMERCIAL-00-03-09 | New policy |
|---|
| Aug 2, 2026 | Independence Blue Cross | Wound Care: Skin Substitutes for the Treatment of Burns and Chronic, Non-Healing WoundsPayerPolicy · IBX-COMMERCIAL-11-08-20AS-5B16B589B1 | New policy |
|---|
| Aug 2, 2026 | Independence Blue Cross | Wireless Capsule Endoscopy for Gastrointestinal (GI) DisordersPayerPolicy · IBX-COMMERCIAL-07-05-02 | New policy |
|---|
| Aug 2, 2026 | Independence Blue Cross | Wheelchair Options and AccessoriesPayerPolicy · IBX-COMMERCIAL-05-00-67 | New policy |
|---|
| Aug 2, 2026 | Independence Blue Cross | Wheelchair Cushions and SeatingPayerPolicy · IBX-COMMERCIAL-05-00-55 | New policy |
|---|
| Aug 2, 2026 | Independence Blue Cross | Voretigene Neparvovec-rzyl (Luxturna)PayerPolicy · IBX-COMMERCIAL-08-01-44 | New policy |
|---|
| Aug 2, 2026 | Independence Blue Cross | VeriStrat Testing for Targeted Therapy in Non-Small Cell Lung CancerPayerPolicy · IBX-COMMERCIAL-06-02-49 | New policy |
|---|
| Aug 2, 2026 | Independence Blue Cross | Ventricular Assist Devices (VADs)PayerPolicy · IBX-COMMERCIAL-11-02-16 | New policy |
|---|
| Aug 2, 2026 | Independence Blue Cross | Velmanase alfa (Lamzede)PayerPolicy · IBX-COMMERCIAL-08-02-04 | New policy |
|---|
| Aug 2, 2026 | Independence Blue Cross | Vedolizumab (Entyvio) for Injection for Intravenous UsePayerPolicy · IBX-COMMERCIAL-08-01-18 | New policy |
|---|
| Aug 2, 2026 | Independence Blue Cross | Vectra DA Blood Test for Rheumatoid ArthritisPayerPolicy · IBX-COMMERCIAL-06-02-45 | New policy |
|---|
| Aug 2, 2026 | Independence Blue Cross | Valoctocogene roxaparvovec-rvox (ROCTAVIAN)PayerPolicy · IBX-COMMERCIAL-08-02-09 | New policy |
|---|
| Aug 2, 2026 | Independence Blue Cross | Vagus Nerve Stimulation (VNS)PayerPolicy · IBX-COMMERCIAL-11-15-16 | New policy |
|---|
| Aug 2, 2026 | Independence Blue Cross | Uterine Artery EmbolizationPayerPolicy · IBX-COMMERCIAL-11-06-04 | New policy |
|---|
| Aug 2, 2026 | Independence Blue Cross | Ustekinumab for Intravenous InfusionPayerPolicy · IBX-COMMERCIAL-08-00-82 | New policy |
|---|
| Aug 2, 2026 | Independence Blue Cross | Use of a Robotic-Assisted Surgical SystemPayerPolicy · IBX-COMMERCIAL-11-00-18 | New policy |
|---|
| Aug 2, 2026 | Independence Blue Cross | Upper Limb ProsthesesPayerPolicy · IBX-COMMERCIAL-05-00-72 | New policy |
|---|
| Aug 2, 2026 | Independence Blue Cross | Ultraviolet Light Therapy for the Treatment of Dermatological ConditionsPayerPolicy · IBX-COMMERCIAL-07-07-02 | New policy |
|---|
| Aug 2, 2026 | Independence Blue Cross | Ublituximab-xiiy (Briumvi) for intravenous usePayerPolicy · IBX-COMMERCIAL-08-02-02 | New policy |
|---|
| Aug 2, 2026 | Independence Blue Cross | Tumor Treating FieldsPayerPolicy · IBX-COMMERCIAL-07-03-26 | New policy |
|---|
| Aug 2, 2026 | Independence Blue Cross | Trilaciclib (Cosela)PayerPolicy · IBX-COMMERCIAL-08-01-77 | New policy |
|---|
| Aug 2, 2026 | Independence Blue Cross | Trigger Point InjectionsPayerPolicy · IBX-COMMERCIAL-11-14-02 | New policy |
|---|
| Aug 2, 2026 | Independence Blue Cross | Triamcinolone Acetonide Extended-Release Injectable (Zilretta)PayerPolicy · IBX-COMMERCIAL-08-01-47 | New policy |
|---|
| Aug 2, 2026 | Independence Blue Cross | Treatments for Complex Regional Pain Syndrome (CRPS)PayerPolicy · IBX-COMMERCIAL-08-00-57 | New policy |
|---|
| Aug 2, 2026 | Independence Blue Cross | Treatment of Varicose Veins of the Lower Extremities and Perforator Vein IncompetencePayerPolicy · IBX-COMMERCIAL-11-02-01 | New policy |
|---|
| Aug 2, 2026 | Independence Blue Cross | Treatment of Pulmonary Artery Hypertension with Intravenous, Subcutaneous, and Inhaled Pharmacologic AgentsPayerPolicy · IBX-COMMERCIAL-08-00-25 | New policy |
|---|
| Aug 2, 2026 | Independence Blue Cross | Treatment of Obstructive Sleep Apnea (OSA) and Primary SnoringPayerPolicy · IBX-COMMERCIAL-11-00-06 | New policy |
|---|
| Aug 2, 2026 | Independence Blue Cross | Treatment of Medical and Surgical ComplicationsPayerPolicy · IBX-COMMERCIAL-11-00-02 | New policy |
|---|
| Aug 2, 2026 | Independence Blue Cross | Trastuzumab (Herceptin) and Related Biosimilars, Trastuzumab and Hyaluronidase-oysk (Herceptin Hylecta)PayerPolicy · IBX-COMMERCIAL-08-00-33 | New policy |
|---|
| Aug 2, 2026 | Independence Blue Cross | Transcutaneous Electrical Nerve Stimulators (TENS) and Associated SuppliesPayerPolicy · IBX-COMMERCIAL-05-00-74 | New policy |
|---|
| Aug 2, 2026 | Independence Blue Cross | Transcatheter Cardiac Valve ProceduresPayerPolicy · IBX-COMMERCIAL-11-02-25 | New policy |
|---|
| Aug 2, 2026 | Independence Blue Cross | Transcatheter Arterial Chemoembolization (TACE) of Hepatic MalignanciesPayerPolicy · IBX-COMMERCIAL-07-05-06 | New policy |
|---|
| Aug 2, 2026 | Independence Blue Cross | Total Parenteral Nutrition (TPN) / Intradialytic Parenteral Nutrition (IDPN) / Intraperitoneal Parenteral Nutrition (IPN)PayerPolicy · IBX-COMMERCIAL-08-00-17 | New policy |
|---|
| Aug 2, 2026 | Independence Blue Cross | Toripalimab-tpzi (Loqtorzi)PayerPolicy · IBX-COMMERCIAL-08-02-20 | New policy |
|---|
| Aug 2, 2026 | Independence Blue Cross | Tofersen (Qalsody)PayerPolicy · IBX-COMMERCIAL-08-02-06 | New policy |
|---|